A Multi-Center, Prospective, Randomized, Controlled Clinical Trial Comparing the Safety and Effectiveness of ProDisc-C to Anterior Cervical Discectomy and Fusion (ACDF) Surgery in the Treatment of Symptomatic Cervical Disc Disease (SCDD)

Synthes USA HQ, Inc.0 sites368 target enrollmentAugust 1, 2003

ConditionsSymptomatic Cervical Disc Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Symptomatic Cervical Disc Disease
Sponsor: Synthes USA HQ, Inc.
Enrollment: 368
Primary Endpoint: Overall Success
Status: Completed
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The objective of this clinical investigation is to compare the safety and effectiveness of ProDisc-C to anterior cervical discectomy and fusion (ACDF) surgery in the treatment of symptomatic cervical disc disease (SCDD).

Registry

clinicaltrials.gov

Start Date

August 1, 2003

End Date

March 1, 2015

Last Updated

8 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Synthes USA HQ, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Symptomatic cervical disc disease (SCDD) in one vertebral level between C3-C7 defined as: Neck or arm (radicular) pain; and/or a functional/neurological deficit with at least one of the following conditions confirmed by imaging (CT, MRI or X-rays): Herniated nucleus pulposus; Spondylosis (defined by the presence of osteophytes); and/or Loss of disc height.
•Age between 18 and 60 years.
•Unresponsive to non-operative treatment for approximately six weeks or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment.
•NDI score greater than or equal to 15/50 (30%).
•Psychosocially, mentally and physically able to fully comply with the protocol including adhering to follow-up schedule and requirements and filling out forms.
•Signed informed consent.

Exclusion Criteria

•More than one vertebral level requiring treatment.
•Marked cervical instability on resting lateral or flexion/extension radiographs: translation greater than 3mm and/or greater than 11 degrees of rotational difference to that of either adjacent level.
•Has a fused level adjacent to the level to be treated.
•Radiographic confirmation of severe facet joint disease or degeneration.
•Known allergy to cobalt, chromium, molybdenum, titanium or polyethylene.
•Clinically comprised vertebral bodies at the affected level(s) due to current or past trauma, e.g. by the radiographic appearance of fracture callus, malunion or nonunion.
•Prior surgery at the level to be treated.
•Severe spondylosis at the level to be treated as characterized by any of the following: Bridging osteophytes; A loss of disc height greater than 50%; or Absence of motion (\<2°).
•Neck or arm pain of unknown etiology.
•Osteoporosis: A screening questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation), will be used to screen patients who require a DEXA (dual energy x-ray absoptiometry) bone mineral density measurement. If DEXA is required, exclusion will be defined as a DEXA bone density measured T score less than or equal to -2.5 (the World Health Organization definition of osteoporosis).

Outcomes

Primary Outcomes

Overall Success

Time Frame: 84 Months

Sponsor Definition of Overall Success: (1) Subject's NDI score improved by at least 20% over preoperative baseline value (2) Subject's neurologic parameters, i.e. motor, sensory, and reflexes were maintained or improved as compared to preoperative baseline value (3) No removals, revisions, re-operations, or additional fixation were required to modify any implant (4) No adverse events occurred which were related to the treatment, ProDisc-C or its implantation or ACDF surgery or its associated implants or graft material